CagriSema 1.7 mg and 1.0 mg each cut bodyweight more than placebo in REDEFINE 9
In a phase 3b trial of adults with obesity or overweight and no diabetes, both lower CagriSema dose levels were superior to placebo for bodyweight loss at 68 weeks. At week 68, mean bodyweight fell by 20.7% (1.7 mg each), 21.0% (1.0 mg each) and 2.0% (pooled placebo), efficacy estimand. Most adverse events were mild or moderate and gastrointestinal. No deaths were reported. The trial was funded by Novo Nordisk, measured weight rather than clinical outcomes, and the abstract does not report a direct comparison of the two doses. Online version: https://www.diabesityrounds.com/a/cagrisema-1-7-mg-and-1-0-mg-each-cut-bodyweight-more-than-placebo-in-redefine-9
Authors
- Diabesity Rounds
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-16
- DOI
- https://doi.org/10.5281/zenodo.24300392
- Primary Topic
- Pharmacology and Obesity Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00